| Identification | Back Directory | [Name]
AB-CHMINACA | [CAS]
1185887-21-1 | [Synonyms]
ABCH
AB-CHMINACA
ADB-FUBINACA
MAB-AB-CHMINACA
AMB N-methylcyclohexyl analog
AB-CHMINACA (exempt preparation)
AB-CHMINACA 3-Methyl butanoic Acid
AB-CHMINACA (1.0 mg/mL in Methanol)
methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-valinate
N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide
N-[(1S)-1-(AMINOCARBONYL)-2-METHYLPROPYL]-1-(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE
1H-Indazole-3-carboxamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)- | [Molecular Formula]
C20H28N4O2 | [MOL File]
1185887-21-1.mol | [Molecular Weight]
356.46 |
| Chemical Properties | Back Directory | [Boiling point ]
625.8±35.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [solubility ]
DMF: 5 mg/ml; DMSO: 10 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml; Ethanol: 3 mg/ml | [form ]
A neat solid | [pka]
11.37±0.46(Predicted) |
| Hazard Information | Back Directory | [Description]
AB-CHMINACA (CRM) (Item No. 27237) is a certified reference material categorized as a synthetic cannabinoid. It has been found in Spice-type herbal blends and is associated with slurred speech, confusion, lethargy, and lack of coordination in cases of driving under the influence. AB-CHMINACA is regulated as a Schedule I compound in the United States. AB-CHMINACA (CRM) (Item No. 27237) is provided as a DEA exempt preparation. This product is intended for research and forensic applications. | [Uses]
AB-CHMINACA is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA, a high affinity ligand of the central CB1 receptor. Synthetic Cannabinoids | [References]
[1] BRIANNA L PETERSON Fiona J C. Concentrations of AB-CHMINACA and AB-PINACA and Driving Behavior in Suspected Impaired Driving Cases.[J]. Journal of analytical toxicology, 2015, 39 8: 642-647. DOI: 10.1093/jat/bkv091
[2] KHALED MASOUD MOHAMED MASOUD Alanoud M A Syed Mujeebuddin Syed. Analyte protectant approach to protect amide-based synthetic cannabinoids from degradation and esterification during GC–MS analysis[J]. Journal of Chromatography A, 2024, 1730: Article 465022. DOI: 10.1016/j.chroma.2024.465022
[3] SOHEIR ALI MOHAMMAD. Toxic effects of AB-CHMINACA on liver and kidney and detection of its blood level in adult male mice.[J]. Forensic Toxicology, 2024: 7-17. DOI: 10.1007/s11419-023-00670-0
[4] MONICA PATEL . Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists[J]. Biochemical pharmacology, 2020, 175: Article 113871. DOI: 10.1016/j.bcp.2020.113871
[5] K. MINAKATA. Sensitive quantification of 5F-PB-22 and its three metabolites 5F-PB-22 3-carboxyindole, B-22 N-5-hydroxypentyl and PB-22 N-pentanoic acid in authentic urine specimens obtained from four individuals by liquid chromatography–tandem mass spectrometry[J]. Forensic Toxicology, 2017, 36 1: 151-159. DOI: 10.1007/s11419-017-0395-4
[6] CLAUDIO ERRATICO. In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA[J]. Drug Testing and Analysis, 2015, 7 10: 866-876. DOI: 10.1002/dta.1796 |
|
|